<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02865733</url>
  </required_header>
  <id_info>
    <org_study_id>SJTUMS-201607</org_study_id>
    <nct_id>NCT02865733</nct_id>
  </id_info>
  <brief_title>Study of Remodulin® in Pediatric Pulmonary Hypertension With Single Ventricular Physiology After Fontan Surgery</brief_title>
  <official_title>Randomized Single-blind Study of Intravenous Maintenance of Remodulin® for the Treatment of Pulmonary Hypertension After Fontan Operation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Jiao Tong University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to determine the safety and efficiency of Remodulin®（Treprostinil&#xD;
      Injection）to reduce the pulmonary arterial pressure and prevent pulmonary hypertension (PH)&#xD;
      after Fontan operation with univentricular physiology.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PH is a significant contributor to the postoperative morbidity and mortality of congenital&#xD;
      heart disease, especially after Fontan operation with univentricular physiology. Mild&#xD;
      increase of pulmonary vascular resistance may lead to failure of Fontan circulation.&#xD;
      Remodulin® has been approved for the treatment of adults with PH, but little is known about&#xD;
      the effects in children with PH after Fontan operation. The study aim is to determine the&#xD;
      safety and efficiency of Remodulin® to reduce the pulmonary arterial pressure and prevent PH&#xD;
      in children after Fontan operation. Meanwhile pharmacokinetics of the drug were checked with&#xD;
      or without the peritoneal dialysis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 1, 2016</start_date>
  <completion_date type="Actual">August 20, 2019</completion_date>
  <primary_completion_date type="Actual">December 31, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary end point is a composite variable</measure>
    <time_frame>the first 48 hours after Remodulin used</time_frame>
    <description>consisting of death, failing Fontan or failed Fontan according to high pulmonary vascular resistance</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from base line of pulmonary hemodynamic measurements</measure>
    <time_frame>baseline and 48 hours</time_frame>
    <description>Pp/Ps reduce &gt;10% or TPG≤6mmHg.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Pulmonary Hypertension</condition>
  <arm_group>
    <arm_group_label>Remodulin Injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: Remodulin Injection Dosage:5 ng/kg/min-80ng/kg/min(0.15ml/hr-2.4ml/hr) Frequency: intravenous maintenance increase at a rate of 10ng/kg/min (0.3ml/hr)every 30 minutes Durations:48 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Distilled water group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Drug:distilled water Dosage:0.15ml/hr-2.4ml/hr Frequency:increase at a rate of 0.3ml/hr every 30 minutes Durations:48 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remodulin</intervention_name>
    <description>After Fontan operation, the mean pulmonary arterial pressure (mPAP)evaluated by CVP or transpulmonary pressure gradient(TPG) evaluated by Echo will be measured firstly, if the data met the criteria, and the patients were enrolled in the experimental group, the patients would be administrated intravenously of Remodulin® with the beginning of 5ng/kg/min, with the rate of 10ng/kg/min every 30 minutes up to 80ng/kg/min.</description>
    <arm_group_label>Remodulin Injection</arm_group_label>
    <other_name>Treprostinil Injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>distilled water</intervention_name>
    <description>After Fontan operation, the mPAP (evaluated by CVP) or TPG (evaluated by Echo) will be measured firstly, if the data met the criteria, and the patients were enrolled in placebo group, then the patients would be administrated intravenously of distilled water with the beginning of 0.15ml/hr, with the rate of 0.3ml/hr every 30 minutes up to 2.45ml/hr.</description>
    <arm_group_label>Distilled water group</arm_group_label>
    <other_name>placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        After Fontan procedure, the criteria should be met&#xD;
&#xD;
          1. mPAP greater than 15 mmHg&#xD;
&#xD;
          2. TPG greater than 6 mmHg (exclude the obstruction of cavopulmonary anastomosis)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        After Fontan surgery :&#xD;
&#xD;
          1. Severe arrhythmia led to low cardiac output&#xD;
&#xD;
          2. Platelets smaller than 50,000*109/L and obvious bleeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhuoming Xu, M.D.,Ph,D.</last_name>
    <role>Study Director</role>
    <affiliation>Cardiac intensive Care Unit,Department of Thoracic and Cardiovascular Surgery</affiliation>
  </overall_official>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>August 1, 2016</study_first_submitted>
  <study_first_submitted_qc>August 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 12, 2016</study_first_posted>
  <last_update_submitted>October 26, 2020</last_update_submitted>
  <last_update_submitted_qc>October 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Jiao Tong University School of Medicine</investigator_affiliation>
    <investigator_full_name>Xu Zhuoming</investigator_full_name>
    <investigator_title>chief cadiologist,Director of Cardiac intensive Care Unit</investigator_title>
  </responsible_party>
  <keyword>Remodulin®</keyword>
  <keyword>pulmonary vascular resistance</keyword>
  <keyword>univentricular physiology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Treprostinil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

